This is not about BDX, but about the sector. BDX and several others are well run companies. This is a great buying opportunity.
I understand the surge of selling, but my questions is WHO is buying??????? I would like to see a lot more insider buying in order to have confidence in this stock.
B Braun has the LidoSite system that is soooo much easier to use than the Sontra system for lidocaine delivery. I don't see how Sontra has a chance.
I think the greatest threat to BD's insulin sringe business is from the new multi-dose prefilled pen systems now gaining market share. But BD says it has done a great job of capturing market share of the disposable needles that are used with these new pen systems.
I think BD is a great manufacturing and sales organization with a stable of much needed products. And I understand that they have to introduce new safey products to defend their core hypodermic business. But in reading their annual reports of late, I don't see the same emphasis on innovation and R&D that they had a few years ago. I was getting excited looking a their attempts to introduce some interesting and very different new products and businesses (e.g., BD.id, transdermal drug delivery, home diabetes tests, etc. Now, they seemed to have cut back in R&D spending and their innovation message seems to have cooled considerably. What happened? Can anyone shed any light? I am concerned about the sustainability and growth after safety products.
I had heard something about BD letting go of Edelman's technoloy and agreement. Can you tell me more about what happened between BD and Edelman?
I could not support your comments more. The answer to their performance (or lack thereof according to some) is - management. Time for a change??
I think laeihs and Hoiwdydoody500 are correct. Look at the dismal top line growth - when will their safety products and biosciences stories kick in? CFO said a few months ago that they are now hedging FX - where are the results? No bold new products in the pipeline - the Probetec performance problem has now finally been admitted - R&D continues to be cut - core products (syringes, etc.) are off and their internal infrastructure is still too heavy. No wonder there is no confidence in next year. BDX has a serious leadership problem. The company can turn around - but not soon with this crew. My guess is that future earnings reports will probabaly continue to be a challenging read.
I believe it was because Cygnus had not met the
technical milestones that BD required and Cygnus' previous
management did not want to re-negotiate the agreement - so
BD walked. They mentioned this in several analyst
meetings back then. BD says they are still working on a
glucose meter and strips, but it remains to be seen
whether BD is willing to put the marketing investment
behind it to capture share. This will be tough for BD to
do since they will be going up against J&J and
Abbott at the same time.
Brigid Healy was hired several years ago as the
heir to Galiardo's General Counsel's slot.
was promoted to Vice Chairman since he was one of he
good old boys but in essence ran the law department.
Hallenback was an interim boss while Healy was earning her
spurs and was been checked out. Remember that Healy was
a partner at a Wall St law firm prior to coming to
BD. Nothing is up. It gives Hallenback an opportunity
to get into operations.